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Probiotics as a treatment 
for prenatal maternal anxiety 
and depression: a double‑blind 
randomized pilot trial
Pamela D. Browne1,2*, Antoinette C. Bolte3, Isolde Besseling‑van der Vaart4, Eric Claassen2 & 
Carolina de Weerth1*
Probiotic use may be an efficacious treatment option to effectively manage symptoms of prenatal 
maternal anxiety and depression. Our primary aim was to test feasibility and acceptability for 
a probiotic randomized controlled trial (RCT) in pregnant women with pre‑existing symptoms. 
This double‑blind pilot RCT included 40 pregnant women with low‑risk pregnancies and elevated 
depressive symptoms and/or anxiety. Once daily, participants orally consumed a probiotic (Ecologic 
Barrier) or a placebo, from 26 to 30 weeks gestation until delivery. A priori key progression criteria for 
primary outcomes were determined to decide whether or not a full RCT was feasible and acceptable. 
Secondary outcomes included depressive symptoms, anxiety, stress, and maternal bonding to 
offspring. In 19 months, 1573 women were screened; following screening, 155 women (10%) were 
invited for participation, of whom 135 (87%) received study information, and 40 women (30%) were 
included. Four out of six a priori determined criteria for success on feasibility and acceptability were 
met. After 8 weeks of intervention, there was no significant difference between the probiotic and 
placebo groups for secondary outcomes. The pilot trial was feasible and acceptable, but hampered by 
recruitment method and study design. Secondary endpoints did not reveal differences between the 
groups for improving maternal mood.
Abbreviations
APL  Dutch Everyday Problem List
CRF  Case Report Form
EPDS  Edinburgh Postnatal Depression Scale
CI  Coordinating investigator
LEIDS-R  Leiden Index of Depression Sensitivity-Revised
MAAS  Maternal Antenatal Attachment Scale
ETC  Medical Ethics Committee
MPAS  Maternal Postnatal Attachment Scale
PSQI  Pittsburgh Sleep Quality Index
PES  Pregnancy Experience Scale
PRAQ-R  Pregnancy-Related Anxiety Questionnaire-Revised
RCTs  Randomized clinical trials
STAI-S  State-trait Anxiety Inventory
AEs  Serious Adverse Events
Prenatal maternal depression and anxiety are risk factors for adverse outcomes in mothers and  children1,2. Simple 
treatments that effectively manage these symptoms in most women are greatly  lacking3. This emphasizes the 
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value of investigating potential efficacious adjuvant treatment options for pregnant women with these symptoms. 
Increased depressive symptoms and heightened anxiety are suggested to have a complex and multi-factorial etiol-
ogy with multiple factors interacting and contributing to the development of  symptoms4. These factors include 
personal resources, predisposing demographic factors, antenatal  stressors5,6, and socio-cultural  beliefs7. Other 
factors include physiological and epigenetic  factors8, and possibly gut  microbiota9,10.
The gut microbiota is suggested to communicate with the brain through nervous, endocrine, and immune 
signaling mechanisms, also referred to as the ‘microbiota-gut-brain-axis’11,12. Via this axis, alterations in the 
gut microbiota composition may contribute to the development of depressive and anxiety  symptomatology13,14. 
Probiotics can affect gut microbiota and hence may reduce depressive symptoms and/or heightened anxiety 
in people with pre-existing  symptoms9,15,16. Probiotics are defined as “live organisms that, when consumed in 
adequate amounts, confer a health benefit to the host”17. A randomized double-blind placebo-controlled trial 
(RCT) in pregnant women found that probiotics ingested during the perinatal period reduced depressive and 
anxiety symptoms during the postnatal  period10. To date, no RCTs exist that investigate the possible efficacy of 
probiotics to improve maternal mood prenatally.
In psychology and medicine, RCTs are considered “gold standard” to evaluate therapeutic efficacy of new 
 treatments18,19. Success of an RCT is largely determined by adequate recruitment of participants and compliance 
with the study protocol during a RCT 20,21. Inadequate recruitment and non-compliance have negative conse-
quences for participants, investigators, and in some cases public funds, and should therefore be  prevented22,23. 
Pilot trials provide an excellent method to avoid these issues by assessing feasibility (i.e., whether potential 
participants would be willing to participate in the trial) and acceptability (i.e., whether the design of the trial is 
acceptable to participants) of a full RCT 24.
The primary aim of this pilot RCT was to evaluate the feasibility in terms of recruitment and retention, and 
acceptability in terms of compliance and participants’ experiences of daily probiotic intake and the collection of 
data. The secondary aim of the present study was to exploratorily investigate the potential effects of probiotic 
intake, compared to placebo, on depressive symptoms, anxiety, stress (from here on named ‘psychosocial dis-
tress’), and by potentially affecting mood, maternal bonding to the  offspring25,26.
Methods
Pilot RCT . The current pilot trial evaluated the feasibility and acceptability of a full RCT (a prenatal interven-
tion on perinatal outcomes). Hence, the study design of the current pilot RCT reflected the design of the poten-
tial full RCT. The design reflects an integrative research approach combining both validated questionnaires and 
biological measures. This approach has been shown successful in many of our previous  studies27–31 and previous 
probiotic  trials9. A description of the ethics, participants, in- and exclusion criteria, trial design, randomization, 
blinding, treatment allocation and sample size of the pilot trial are provided below. Full details about the proce-
dures, methods and outcome measures are described in detail in a separate  paper32.
Ethics. The Medical Ethics Committee (METC) of the Radboud University Medical Center in Nijmegen, 
the Netherlands (NL57780.091.16) approved the study. Study procedures were conducted in accordance with 
the Helsinki Declaration of 1975 as revised in 1983. The trial was registered under trial number NTR6219 on 
28/02/2017 (Netherlands Trial Register).
Participants. Forty healthy pregnant women (≥ 18 years) with at least mild depressive symptoms and/or anxi-
ety in the late second/third trimester of an uncomplicated pregnancy (≥ 26 and ≤ 30 weeks gestation) partici-
pated in this study.
Inclusion and exclusion criteria. Inclusion criteria were: (1) elevated levels of depressive symptoms (EPDS ≥ 10) 
and/or anxiety (STAI-S ≥ 40), (2) start daily probiotic/placebo product intake between 26 and 30 weeks gesta-
tional age and continue until delivery. Exclusion criteria include: (1) multiple pregnancy, (2) high suicidal risk 
according to the suicidality subscale score on the MINI International Neuropsychiatric Interview, (3) illegal 
drug use, (4) psychiatric history of psychoses or bipolar disorder, (5) inflammatory bowel disease, (6) other auto-
immune disorders and/or treatment with immunosuppressive therapy, (7) known pre-existing diabetes mellitus, 
hyperemesis gravidarum, hypertensive disorder, liver and/or renal disease, (8) malignancy and/or treatment 
with radiation or chemotherapy, (9) history of major gastro-intestinal surgery, (10) allergy or hypersensitivity 
to any ingredients in the Ecologic Barrier/placebo product, (11) history of using Ecologic Barrier, (12) presently 
using food containing probiotics (probiotic intake needed to stop at least 2 weeks prior to the start of the probi-
otic/placebo product intake), (13) not speaking and/or writing  Dutch32.
Trial design. From 26 to 30  weeks gestation until delivery, participants once daily orally consumed 
a probiotic multispecies mixture (Ecologic Barrier; 2.5 × 109  CFU/g; daily dosage 2  g; Bifidobacterium 
bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophi-
lus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus 
lactis W19 and Lactococcus lactis W58) or a placebo. The probiotic product and placebo were indistinguishable 
regarding color, taste, and smell (Winclove Probiotics BV, Amsterdam, the Netherlands). Given that a poten-
tial full RCT would not investigate probiotics as a single management option for psychosocial distress, but the 
potential effectiveness in addition to participants’ current treatment, the use of any kind of co-medication or 
therapy was allowed.
To assess the potential effect of prenatal probiotic intake compared to placebo on perinatal maternal psycho-
social distress women filled in questionnaires at baseline (time point 0 (t0)) and 8 weeks after starting probiotic/
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placebo intake (time point 1 (t1)). Additionally, to assess the potential long-term effects of prenatal maternal 
probiotic intake, maternal mood and maternal bonding to offspring were assessed 4 weeks post-partum (time 
point 2 (t2)).
Randomization, blinding, and treatment allocation. Forty women were randomly allocated to either the probi-
otic group or placebo group by a computer random number algorithm (1:1 allocation ratio), using blocks of four. 
Research personnel, who provided the probiotic or placebo and collected data, and participants were blinded 
to the treatment assignment and uninformed about the randomization sequence. Outcome assessors were also 
blinded to the treatment assignment. Further details on the intervention, intake, randomization and probiotic/
placebo delivery procedure can be found in the protocol  manuscript32.
Sample size. A sample size of 40 participants (~ 27% of a full trial) was deemed appropriate to inform about 
the primary outcomes. Based on a previous study by Steenbergen et al. (2015), which investigated the effect of 
the same probiotic product on mood in a non-pregnant healthy population, this sample size was also regarded 
sufficient to exploratorily assess the potential effects of  probiotics33.
Primary outcomes of the pilot RCT . The primary outcomes of this pilot RCT were the feasibility and 
the acceptability. Feasibility was assessed in terms of recruitment (i.e., the proportion of pregnant women with 
psychosocial distress accepting the invitation to participate in the pilot trial and reasons for (non) participation) 
and retention (i.e., the number of women completing the study from enrolment to follow-up). Acceptability was 
measured in terms of compliance (i.e., the proportion of participants adhering to the intervention schedule and 
the collection of data) and participants’ experiences during the pilot trial. Based on these primary outcomes, six 
a priori key progression criteria were established, see Table 1. Not meeting one or more key progression criteria 
indicates that the study protocol needs to be revised before conducting a full RCT.
Recruitment. In order to recruit 40 participants, local advertisement to participate in an online questionnaire 
study on mood and experiences during pregnancy was provided at six sites in the Netherlands: two ultrasound 
centers, an academic hospital, a lactation consultant practice, and two mental health centers. Participants meet-
ing the criteria for inclusion were invited to participate in the pilot RCT; they were included in the study after 
providing written informed consent. Additional information of the way participants were identified and consent 
was obtained can be found in the protocol  publication32.
Retention. The proportion of participants completing the study from enrolment (t0) to follow-up (t2) was 
recorded on Case Report Forms (CRFs) throughout the study.
Compliance. Data on the proportion of participants taking ≥ 80% probiotic/placebo product was collected at t2 
by the CI by counting the sachets that were left from the previous weeks.
Participants’ experiences. A self-created evaluation form was used to assess participants’ experiences during the 
pilot trial. The questionnaire included nine questions in total. Five open questions on experiences of filling in 
questionnaires during the pilot trial (i.e., length, number of questionnaires, electronic method), the collection of 
maternal/infant stool and vaginal samples (i.e., number of samples, explanation about the method of collection, 
potential difficulties in collecting samples), and the collection of the hair sample; and two open questions on 
the level of satisfaction (“Regarding the study in general, which aspects did you experience as most positive and 
negative?” “Do you have any general remarks regarding execution and organization of this study?”). Addition-
ally, two closed questions on the level of satisfaction were included (i.e., acceptability of the pilot trial in principle 
and in practice). To rate the acceptability of the pilot trial in principle, participants indicated the likelihood of 
participating in a similar trial in the future (0 = ‘no chance of future participation’ to 10 = ‘very high chance of 
future participation’); for the acceptability of the pilot trial in practice participants rated on a scale of 0 to 10 the 
perceived burden of the trial (0 = ‘no burden’ to 10 = ‘very large burden’).
Secondary outcomes of the pilot RCT . A brief description of all measurement tools used can be found 
below; an elaborate description, as well as a description of other measures not used in the analyses for the current 
manuscript, is provided in the protocol  paper32.
Demographic characteristics. Participants filled out questionnaires on demographics, health behavior and life-
style. Demographic variables were collected during the screening phase (time point -1 (t-1)).
Maternal depressive symptoms. Edinburgh Postnatal Depression Scale. Pre- and postnatal depressive symp-
toms were measured using the Edinburgh Postnatal Depression Scale (EPDS), which is a validated tool to screen 
for antenatal and postnatal depressive  symptoms34. The EPDS consists of 10-items scored on a 4-point scale 
with a maximum score of 30. A sum score of 10 or more was considered to reflect the presence of at least mild 
depressive  symptoms35.
Leiden Index of Depression Sensitivity-Revised. Negative thoughts associated with sad mood, as a predictor of 
depression, was measured with the validated Leiden Index of Depression Sensitivity-Revised (LEIDS-R)36. The 
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questionnaire consists of 34 items for which participants indicate to what extent each statement applies to them 
on a 5-point Likert scale. A higher total score indicates more cognitive reactivity to sadness, which indicates a 
potential larger tendency to develop depression.
Maternal anxiety. Pregnancy-Related Anxiety Questionnaire-Revised (Pregnancy-related anxiety). Preg-
nancy-specific anxiety was measured using the Pregnancy Related Anxiety Questionnaire-Revised (PRAQ-R), 
which is a validated 10-item tool scored on 5-point scale that screens for pregnancy-related anxiety in pregnant 
 women37. Two subscales “fear of giving birth” and “fear of bearing a handicapped child” were used. Higher scores 
on these subscales indicate more pregnancy-related anxiety.
State-trait Anxiety Inventory (general anxiety). The state version of the State-trait Anxiety Inventory (STAI-S), 
a validated self-report questionnaire for pregnant women, was used to measure general  anxiety38. The STAI-S 
consists of 20 statements related to current feelings of anxiety, which are scored on a 4-point Likert scale (maxi-
mum score of 80). Higher scores indicate more general feelings of anxiety. A cut-off score of 40 has been shown 
to have high sensitivity and specificity among pregnant women in their third trimester of pregnancy to detect 
anxiety  disorder39.
Maternal stress. Pregnancy Experience Scale (pregnancy-related daily hassles). The validated Pregnancy 
Experience Scale (PES) was used to measure maternal appraisal of daily, pregnancy-specific hassles and  uplifts40. 
The questionnaire consists of 43-items on which participants rated the degree to which these specific experi-
ences constituted a hassle and uplift on two separate 5-point Likert scales. To calculate the total intensity score 
for hassles, a sum of scores for hassles was calculated and divided by the number of endorsed items for hassles. 
A similar calculation for total intensity score for uplifts was performed. A composite ratio score was computed 
Table 1.  Primary quantitative outcomes, outcome measures and time point for each outcome (i.e., baseline 
(t0), 8 weeks after probiotic/placebo intake (t1) and 4 weeks post-partum (t2), (key) progression criteria for 
a full RCT, and (key) progression criteria that were met (yes/no). Key progression criteria are bold. 1 Full 
completion of the study defined as: the closing home visit has taken place at t2. 2 Of the 34 participants who 
collected biological samples. *Key progression criteria. If one of more key progression criteria is not met 
revisions to study protocol should be made prior to conducting a full RCT.
Primary quantitative outcomes Outcome measure, time point for each outcome Progression criteria for full RCT Progression criteria met (yes/no)
A) Recruitment
1) The proportion of contacted potential par-
ticipants meeting the inclusion criteria and who 
consent to participate in the pilot trial
30 participants recruited in 6 months No (40 participants in 19 months)*
2) The number of participants recruited at each 
recruitment site for the research database No criteria set –
3) Reasons for (non) participation No criteria set –
B) Retention rate 1) The proportion of participants completing the study from enrolment (t0) to follow-up (t2)1  ≥ 90% of participants
Yes (98% of participants completed the pilot 
trial)*
C) Compliance
1) The proportion of participants taking ≥ 80% 
probiotic/placebo product between t0 and t1 90% of participants Yes (90% of participants)*
2) The proportion of participants filling in elec-
tronic questionnaires at all time points 90% of participants Yes (100% of participants)*
3) The proportion of participants filling in the cry 
diary at t2 90% of participants No (85% of participants)
4) The proportion of participants filling in evalu-
ation form at t2 90% of participants Yes (98% of participants)
5) The proportion of participants collecting 
maternal vaginal samples at t0 and t1 90% of participants No (83% of participants)
6) The proportion of participants collecting 
maternal microbial samples at t0 and t1 90% of participants No (85% of participants)
7) The proportion of participants collecting infant 
microbial samples at t2a and t2b 90% of participants No (83% of participants)
8) The proportion of participants allowing collec-
tion of hair samples at t2 90% of participants No (83% of participants)
D) Participants’ experiences
1) Level of acceptability of electronic question-
naires No criteria set -
2) Level of acceptability collection of biological 
 samples2 No criteria set -
3) Level of satisfaction (positive/negative aspect) No criteria set -
4) Level of satisfaction (execution and organiza-
tion) No criteria set -
5) Level of acceptability of the pilot trial in prac-
tice (i.e., perceived burden) Mean score of ≤ 3 No (Mean 4; SD 2.2)*
6) Level of acceptability of the pilot trial in princi-
ple (future participation) Mean score of ≥ 8 Yes (Mean 8; SD 1.7)*
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3051  | https://doi.org/10.1038/s41598-021-81204-9
www.nature.com/scientificreports/
relating hassles to uplifts (i.e., total intensity score for hassles divided by total intensity score for uplifts). A ratio 
larger than 1 indicate more hassles than uplifts (i.e., larger negative emotional valence towards pregnancy); a 
ratio smaller than 1 indicate more uplifts than hassles.
Everyday Problem List (general daily hassles). The validated 49-item Dutch Everyday Problem List (APL) 
measured the occurrence and intensity of general daily hassles during  pregnancy41. Participants indicated which 
specific daily hassles they had experienced and scored on a 4-point Likert scale how much each of them had 
bothered them. The total sum of the Likert scale points was divided by the total number of daily hassles reported. 
A higher value indicate more perceived stress due to daily hassles.
Mother to infant bonding. The Maternal Antenatal Attachment Scale. The validated Maternal Antenatal 
Attachment Scale (MAAS) assessed participant’s bonding with her  fetus42. The MAAS consists of 19 items scored 
on a 5-point Likert scale. Higher total sum scores indicate higher preoccupation with the unborn child and 
higher quality bonding.
The Maternal Postnatal Attachment Scale. The Maternal Postnatal Attachment Scale (MPAS), a validated tool 
among pregnant women, was used to measure the strength of the mother to infant  bonding43. The MPAS ques-
tionnaire consists of 19 items that are scored on a 5-point Likert scale. Higher total sum scores reflect higher 
quality of maternal to infant bonding.
Potential confounders. Previous literature reported several variables that are associated to maternal 
 mood11,44. These include sleep, stressful events, and the use of (non) pharmacological treatments (e.g. yoga-
based interventions)45. Data on these variables were collected at baseline (t0) and 8 weeks after treatment (t1) 
to control for undesired differences between the treatment and placebo groups that may confound potential 
treatment effects.
Sleep. Sleep (i.e., quality and disturbances during the previous month) was measured using the validated Pitts-
burgh Sleep Quality Index (PSQI). The questionnaire consists of 19-items, which are scored on a 4-point Likert 
scale. A total sum score of > 5 indicates poor sleep  quality46.
Stressful events. In the current absence of a validated questionnaire on stressful life events for pregnant women, 
we constructed a 7-item stressful event questionnaire. The items were based on previous literature on predic-
tors of prenatal anxiety and  depression4,47. In the questionnaire, participants listed whether they experienced 
a stressful event (yes/no) during the first eight weeks of probiotic intake. These items included: “sickness of 
oneself ”, “sickness of partner”, “death of a close family member/friend”, “relational/marital problems”, “divorce/
separation”, “financial problems”, “domestic violence”, “other” (See Supplementary Fig. 1). Items were summed 
up so that more reported stressful events were indicative for higher incidence of stressful life events during the 
probiotic/placebo product intake period.
(Non) Pharmacological treatments. Regarding the use of (non) pharmacological treatments, participants were 
asked whether they started to use new (non) pharmacological treatments during the intervention period (yes/
no).
Side effects and serious adverse events. Side effects (“constipation”, “flatulence”, “nausea”, “diarrhea”, “other”) 
were recorded at baseline (t0) and 8 weeks after probiotic/placebo intake (t1). Serious adverse events (SAEs) 
were recorded throughout the study.
Statistical analyses. Qualitative analysis for primary outcomes. Qualitative data were analyzed according 
to the principles of the Framework  approach48. Two researchers (PD and HL; see Acknowledgements) indepen-
dently developed an analytical framework by reading through all responses on the interview questions and by 
coding the transcripts separately. The researchers consequently compared the codes and once agreed to a set of 
codes, grouped them together to form themes and categories to establish an overarching analytical framework. 
The analytical framework was then used to index all transcripts using an Excel spreadsheet chart (Microsoft 
Excel, version 14.6.6, 2011).
Quantitative analyses for primary and secondary outcomes. Demographic characteristics of participants were 
analyzed using descriptive statistics as mean/median and percentages. Following the intention-to-treat principle, 
data of all participants were included in the statistical analyses. Mean/median and frequencies were compared 
using t-tests and Fisher’s exact test, respectively. For each questionnaire, mean total scores were initially com-
pared between placebo and probiotic groups by two-sample independent t-tests to detect between-groups effects 
at baseline (t0), after 8 weeks of probiotic/placebo intake (t1) and 4 weeks post-partum (t2). Data were tested for 
equal variance and where data did not have equal variance, Welsh’s correction was used. To detect within-groups 
differences over time, repeated measures ANOVA were performed with time (t0, t1 and t2) as within-subject 
factor and group (placebo vs. probiotic) as between-subjects factor. Tukey HSD post-hoc test was used to identify 
significant differences in the means between pairs. A p value of < 0.05 was considered significant. All analyses 
were performed with the use of R software (R studio, version 1.1.463, 2018; www.r-proje ct.org). Regarding the 
primary outcome on participants’ experiences, themes and categories were calculated as a percentage of the total 
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number of participants reporting that specific theme or category (see Qualitative analysis for primary outcomes 
for qualitative analysis method).
Results
Preliminary analyses. The probiotic and placebo groups did not significantly differ with regard to 
maternal characteristics (t0; M = 27.8  weeks gestation, SD = 1.5) (independent t-test; Fisher’s exact test) (see 
Table 2). Additionally, there were no significant differences between probiotic and placebo groups for starting 
new (non) pharmacological treatments between pre-treatment (t0; M = 27.8 weeks gestation, SD = 1.5) and t1 
(M = 35.8 weeks gestation, SD = 1.5) (Fisher’s exact test, p > . 05). Furthermore, no significant differences were 
found for the number of reported stressful life events during the first 8 weeks of probiotic intake for participants 
in the probiotic versus placebo group [F(1,38) = 0.176, p > 0.05]. There was a significant effect of time on sleep 
[F(1, 38): 8.72, p < 0.05], with sleep quality worsening over pregnancy for the group as a whole. However, no 
significant effects of time by group interaction were found [F(1,38) = 0.29, p > 0.05]. In conclusion, new (non) 
pharmacological treatments, stressful events, and quality of sleep were not regarded as confounding variables 
for differences between the groups in depressive symptoms, anxiety or stress, and therefore not included in the 
analyses as confounders.
Primary outcomes. Four out of the six key progression criteria were met: 98% of participants completing 
the study (i.e., the closing home visit took place at t2 to finalize the study), 90% of participants taking ≥ 80% 
probiotic or placebo product for eight weeks straight, 100% of participants filling in online questionnaires at all 
time points, and acceptability of the pilot in principle (mean score of 8, SD = 1.7). The progression criterion for 
recruitment (40 participants recruited in 19 months) and the acceptability of the pilot in practice (mean score of 
4, SD = 2.2) were not met (see Table 1).
Recruitment. Participants were recruited from March 2017 to September 2018 for the research database by 
local staff. During the first three months of recruitment (March–May 2017) it appeared that only 2 of the 14 
potential participants consented to participate. In order to improve the recruitment rate, a second echo center 
(September 2017), an academic hospital (November 2017), a lactational practice (December 2017), and two 
mental healthcare centers (January 2018) were additionally added as recruitment sites.
Regarding the recruitment rate, of the 1573 potential participants filling in the online questionnaire, 817 of 
them consented to be included into the research database to be contacted for other research on psychosocial 
distress. Of the 817 women, 155 (19%) scored above the threshold for psychosocial distress and met the study 
inclusion criteria. Most of the 155 women agreed to receive study information (n = 135; 87% of the women con-
tacted by phone) and finally 40 women agreed to participate in the pilot trial (30%) (see Fig. 1).
With respect to the number of participants recruited at each of the recruitment sites for the research database, 
Table 3 shows the recruitment numbers per recruitment site. As can be observed in the table, most participants 
were recruited through the echo centers. At echo center 1, a total of 4147 email invitations were sent to potential 
participants, of which 1088 women fully completed the questionnaire (response rate 26%). Regarding echo center 
2, a total of 596 email invitations were sent and 441 women filled in the questionnaires (response rate 74%). At 
the academic hospital email addresses from potential participants were collected and a link of the online ques-
tionnaire was provided on flyers on site; a total of 20 email invitations were sent to women visiting the academic 
hospital. At the lactational practice and mental healthcare centers, only a link of the online questionnaire was 
provided on flyers and therefore the response rate could not be calculated. 
Regarding reasons for (non) participation, there were four specific moments when participants made the 
decision to join the study: after speaking with researcher by phone, after speaking to midwife, after speaking to 
partner, and after reading study information. For some participants, there was no specific moment when they made 
the decision to join (see Table 4). Four main reasons concerning reasons why participants participated in the 
pilot trial were identified: potential benefits, study topic, familiarity with research, and moral obligation. The most 
widely reported reason to join the study was the potential benefit that participation might bring participants, 
and that participation might help other women, healthcare and science (see Table 5).
Sixty women provided reasons why they did not want to participate after receiving study information. The 
main reason to decline participation was the study design (e.g. the duration of the study being too long, too 
many actions required) (Fig. 2).
Retention. Ninety-eight percent of recruited participants completed the pilot trial. One participant was 
unreachable to schedule the closing visit (see Fig. 1).
Compliance. Thirty-nine participants (98%) complied with the intervention regime of > 80% of probiotic and 
placebo intake during the first 8 weeks. For one participant, compliance was unknown during the first eight 
weeks because of the participant being unreachable to schedule a home visit. Thirty-six women (90% of the total 
population) adhered to probiotic or placebo ingestion of > 80% of probiotic intake between t1 up to delivery. 
Several reasons were reported for non-adherence between t1 and delivery: daily intake posed too much burden 
on daily life (n = 1), not observing an effect on mood (n = 1), receiving new medication and not wanting to ingest 
the sachets and medication in parallel (n = 1). One participant was unreachable at the end of the study. Further-
more, the compliance criterion for the evaluation form was met with 98% of women filling in the evaluation 
form. Other compliance criteria that were not met included: filling in the cry diary and collecting vaginal and 
microbial samples (83–85% compliance rate) (see Table 1). Participants who did not collect these data indicated 
that it posed too much burden on their daily life to fill in the cry diary and/or to collect biological samples.
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Probiotic (N = 20) Placebo (N = 20)
Age (years) [Mean, SD] 29.65 (3.9) 31.7 (4)
Educational level [n (%)]
Lower secondary education 0 (0%) 2 (10%)
Lower secondary vocational education 4 (20%) 3 (15%)
Higher secondary education 1 (5%) 0 (0%)
Tertiary education 15 (75%) 15 (75%)
Number of previous pregnancies [median (IGR)] 1.5 (1.25) 2 (1)
Marital status [n (%)]
Married/registered partnership 15 (75%) 13 (65%)
Unmarried with partner 5 (25%) 6 (30%)
Single 0 (0%) 1 (5%)
Employment status [n (%)]
Employed 16 (80%) 19 (95%)
Unemployed 4 (20%) 1 (5%)
Ethnicity [n (%)]
Dutch 20 (100%) 18 (90%)
Other 0 (0%) 2 (10%)
Weeks gestation at start of intervention [median (IGR)] 28 (2) 28 (2.25)
Psychiatric diagnosis [n (%)]
Depression 1 (5%) 2 (10%)
Anxiety disorder 2 (10%) 2 (10%)
Borderline disorder 0 (%) 1 (5%)
Posttraumatic stress disorder 0 (0%) 1 (5%)
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) 1 (5%) 0 (0%)
History of depression [n (%)]1
Prenatal depression 0 (0%) 1 (5%)
Postpartum depression 2 (20%) 6 (30%)
Non- pharmacological treatment(s) [n (%)] 9 (45%) 6 (30%)
Cognitive behavioral therapy 1 (5%) 2 (10%)
Psychotherapy 2 (10%) 0 (0%)
Rapid eye-movement therapy 1 (5%) 1 (5%)
Psychosocial support 4 (20%) 2 (10%)
Haptotherapy 1 (5%) 1 (5%)
Pharmacological treatment(s) for depression or anxiety [n (%)] 1 (5%) 3 (15%)
Food supplement(s) use [n (%)]2 6 (30%) 3 (15%)
Vitamin(s) use [n (%)] 16 (80%) 18 (90%)
Smoking [n (%)] 0 (0%) 2 (10%)
Alcohol [n (%)] 0 (0%) 0 (0%)
Diet [n (%)]
Lactose free 0 (0%) 1 (5%)
Biological food 0 (0%) 1 (5%)
Gluten free 1 (5%) 0 (0%)
Vegetarian (no meat) 0 (5%) 2 (10%)
Vegan 0 (0%) 0 (0%)
Baseline mood scores [mean (SD)]
Depressive  symptoms3 12.8 (4.3) 12.5 (3.9)
Cognitive  reactivity4 49.4 (10.4) 43.45 (10)
Pregnancy-related anxiety—fear handicapped  child5 8.7 (3) 9.7 (4.5)
Pregnancy-related anxiety—fear of  birth6 7.4 (2.9) 7.65 (3.2)
General  anxiety7 47.75 (9.1) 47.55 (9.9)
General daily hassles (total score)8 0.71 (0.33) 0.71 (0.31)
Pregnancy-related daily hassles (uplifts)9 1.50 (0.43) 1.45 (0.41)
Pregnancy-related daily hassles (hassles)9 0.96 (0.4) 0.99 (0.34)
Mother to infant  bonding10 66.8 (8.04) 65.5 (6.44)
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Participants’ experiences. The progression criterion for level of acceptability of the pilot in principle was met 
(i.e., likelihood of future participation in a trial; mean score of 8, SD = 1.7; scale range = 1–10), but not the accept-
ability of the pilot in practice (mean score of 4, SD = 2.2; scale range = 1–10, lower score indicating lower per-
ceived burden) (see Table 1). Regarding the level of acceptability of electronic questionnaires and collection of 
biological samples, the majority of participants indicated that they found the number of online questionnaires 
during the pilot trial appropriate (95%) and the online method of filling in questionnaires convenient (87%). 
With respect to the collection of maternal stool and vaginal samples, most women indicated that clear user 
guides were provided (88% and 91%, respectively) and that the number of samples to be collected was doable/
appropriate (88% and 76%, respectively). Regarding the collection of infant stool samples, 33% of women indi-
cated that the collection guide was clear and 30% found the number of infant samples to be collected appropri-
ate. Most women indicated that they had no problem with collection of hair (88%), however some women (9%) 
found it a little scary to have hair collected (see Supplementary Fig. 2A–E). Most positive experienced aspects of 
the pilot trial were the personal guidance and interaction with the researcher (37%) and the home visits (24%). 
Most negative experienced aspects were the collection of biological samples (32%) and the ingestion of the pro-
biotic/placebo product (24%) (see Supplementary Fig. 3A,B).
Secondary outcomes. Maternal psychosocial distress (i.e., depressive symptoms, anxiety, stress) was 
scored both pre-treatment (t0; M = 27.8 weeks gestation, SD = 1.5), after 8 weeks of probiotic/placebo intake (t1; 
M = 35.8 weeks gestation, SD = 1.5) and 4 weeks post-partum (t2; M = 4.35 weeks postpartum, SD = 0.8). Note 
that depression/cognitive reactivity to sad mood (LEIDS-R), pregnancy-related anxiety (PRAQ-R), pregnancy-
related hassles (PES), general daily hassles (APL), and antenatal attachment (MAAS) questionnaires were only 
filled in at t0 (M = 27.8  weeks gestation, SD = 1.5) and t1 (M = 35.8  weeks gestation, SD = 1.5). The Maternal 
Postnatal Attachment Scale (MPAS) was filled in at t2 (M = 4.35 weeks postpartum, SD = 0.8). For the secondary 
analyses, all 40 participants were included in the originally assigned groups.
Depression (EPDS). ANOVAs performed on the EPDS score revealed a main negative effect of time 
[F(2,76) = 11.2, p < 0.05]. No effect was observed for group [F(2,38) = 0.8, p > 0.05] nor for a time by group inter-
action [F(2.76) = 0.84, p > 0.05]. Tukey HSD post-hoc tests were performed and revealed that participants in the 
probiotic group had a significant decrease in depressive symptoms between baseline (t0) and 4  weeks post-
partum (t2) (p = 0.04). Similarly, depressive symptoms of women in the placebo group significantly decreased 
between baseline (t0) and 4 weeks postpartum (t2) (p = 0.04). Thus, depressive symptoms decreased in the group 
as a whole from baseline to after the intervention, irrespective of study group (see Fig. 3).
Depression/cognitive reactivity to sad mood (LEIDS-R). ANOVAs on LEIDS-R total score showed a significant 
negative effect of time [F(1,38) = 12.55, p = 0.02] and group [F(1,38) = 5.82, p < 0.001], but no time by group 
interaction [F(1,38) = 0.92, p > 0.05]. Tukey HSD post-hoc test showed that women in the placebo group had 
significantly lower total scores on cognitive reactivity at t0 than women in the probiotic group at t1 (p = 0.001).
General anxiety (STAI-S). Symptoms of general anxiety decreased in both groups. ANOVAs revealed a sig-
nificant negative effect of time on general anxiety [F(1,38) = 10.79, p < 0.05], but not for group [F(1,38) = 0.34, 
p > 0.05] and time by group interaction [F(1,38) = 0.47, p > 0.05]. Tukey HSD post-hoc test revealed that the 
decrease in anxiety was only significant for the total population (p < 0.001) (Fig. 4).
Pregnancy-related anxiety (PRAQ-R). A significant negative effect of time on pregnancy-related anxiety was 
found for the subscale fear of bearing a handicapped child [F(1,38) = 6.37, p < 0.05], but no effect was observed 
for time by group interaction [F(1,38) = 0.7, p > 0.05]. For the subscale fear of giving birth, no significant 
effects of time [F(1,38) = 2.5, p > 0.05], group [F(1,38) = 0.2, p > 0.05], nor time by group interaction were found 
[F(1,38) = 0.28, p > 0.05].
Pregnancy-related daily hassles and general daily hassles (PES and APL). There was a significant negative effect 
of time on pregnancy-related daily hassles (PES composite ratio score; [F(1,38) = 14.6, p < 0.05]) and general 
daily hassles (APL stress score; [F(1,38) = 13.9, p < 0.05]). Tukey HSD post-hoc showed no significant decrease in 
pregnancy-related daily hassles from baseline to t1 in the probiotic group (p = 0.18) or placebo group (p = 0.19). 
Similarly, the decrease in general daily hassles was not significant in neither probiotic nor placebo group (p = 0.37, 
p = 0.38, respectively).
Table 2.  Pre-treatment demographic characteristics of women receiving probiotic or placebo product. 1 Out 
of 10 women in probiotic group and 13 women in placebo group with previous pregnancies. 2 (Homeopathic) 
iron supplements, bee pollen etc. 3 Edinburgh Postnatal Depression Scale (EPDS); scale: 0–3034. 4 Leiden index 
of depression sensitivity-revised (LEIDS-R); scale 0–13651. 5 Pregnancy Related Anxiety Questionnaire-Revised 
(PRAQ-R); scale 3–2037. 6 Pregnancy Related Anxiety Questionnaire-Revised (PRAQ-R); scale 3–1537. 7 State 
Trait Anxiety Inventory (STAI-S); scale: 20–8038. 8 Everyday Problem Checklist (APL); (-1)–141. 9 Pregnancy 
Experience Scale (PES); scale 0–440. 10 Maternal Antenatal Attachment Scale (MAAS); scale 19–9542.
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Figure 1.  Participants’ flow through the study based on the Consolidated Standards of Reporting Trials 
(CONSORT) flow diagram. From the research database, participants were screened for eligibility and 
contacted by phone by the coordinating investigator whether they wanted to receive study information. 
Eligible participants who provided consent were randomized in either the probiotic or placebo group (t0). 
Measurements took place between baseline (t1) and 4 weeks post-partum (t2). Participants were recruited from 
March 2017 to September 2018.
10
Vol:.(1234567890)
Scientific Reports |         (2021) 11:3051  | https://doi.org/10.1038/s41598-021-81204-9
www.nature.com/scientificreports/
Maternal Antenatal Attachment Scale (MAAS). ANOVAs yielded a main positive effect for time on maternal 
attachment score, with maternal attachment increasing for the group as a whole [F(1,38) = 27.8, p < 0.05]. Tukey 
post-hoc test showed no significant time by group interaction (p = 1).
Maternal Postnatal Attachment Scale (MPAS). Women in the probiotic group (M = 67.35, SD = 8.42) and 
women in the placebo group (M = 68.85, SD = 7.08) had comparable attachment scores postpartum (t38 = 0.6, 
p = 0.55).
Side effects and serious adverse events. No significant differences were found in the number of side effects 
and SAEs between the probiotic and placebo groups (Fisher’s exact test, p = 0.16, p = 1, respectively). Seventeen 
participants in the probiotic group and 12 participants in the placebo group reported side effects during intake 
of the probiotic/placebo product. Most reported side effects were constipation (10 probiotic group vs. 5 placebo 
group), flatulence (6 probiotic group vs. 9 placebo group), nausea (7 probiotic group vs. 4 placebo group), and 
diarrhea (5 probiotic group vs. 3 placebo group) during the first 8 weeks of probiotic intake. Four SAEs occurred: 
in the probiotic group, two participants were admitted to the hospital, one for pregnancy induced hyperten-
sion and the second for preterm delivery (34 weeks gestational age). In the placebo group, one participant was 
admitted due to severe headache and another participant had placenta praevia. No SAEs were related to study 
participation.
Table 3.  Recruitment method, recruitment period, number of potential participants who filled in the online 
questionnaire, average number of filled in online questionnaires per month, number of potential participants 
providing consent to be included in the research database rate, and number of included participants per 
recruitment site. 1 The online questionnaire invitation was sent to potential participants 3 weeks after the 
20-week ultrasound. 2 When women visited echo centre 2 for their 20-week ultrasound, personal email 
addresses were collected; 3 weeks thereafter the online questionnaire invitation was sent per email. 3 Flyer with 
link to online questionnaire was located in the waiting room. 4 Percentage of total number of filled in online 
questionnaires per recruitment site.
Recruitment site Recruitment method
Recruitment period 
(Months)
Total number of 
filled in online 
questionnaires (N)
Average number filled 
in online questionnaire 
per month (N)
Number of women 
providing consent 





Echo center 1 Questionnaire invita-tion  sent1 19 1088 57 583 (54%)
4 27 (68%)
Echo center 2 Questionnaire invita-tion  sent2 12 441 37 212 (48%)
4 12 (30%)
Lactational practice Flyer in waiting  room3 8 11 1 5 (45%)4 0 (0%)
Mental healthcare 
center 1 Flyer in waiting  room
3 8 3 0 3 (100%)4 1 (3%)
Mental healthcare 
center 2 Flyer in waiting  room
3 8 0 0 0 (0%) 0 (0%)
Academic hospital Flyer in waiting  room3 10 30 3 14 (48%)4 0 (0%)
Total – 1573 – 817 (52%) 40 (3%)
Table 4.  Description of reported moments of decision to participate in the pilot trial.
Moment Specific elements Representative comments from participants
1. After speaking with researcher by phone
Personal interaction with the researcher, personal approach “After filling in the online questionnaire, I was positive about joining a study, and when I heard you on the phone I decided to join”
Safety reassurance “I decided to join the study after I was able to ask you my remaining questions regarding safety”
Discussing protocol compliance “When I heard that I could leave out the collection of some samples, if it would be too much of a burden for me”
2. After speaking to midwife Midwife’s reassurance and encouragement
“After I spoke with you on the phone, I discussed the study with my 
husband and midwife. The fact that my midwife said that she had also 
thought about advising me to sign up was especially reassuring.”
3. After speaking to partner Partner’s agreement and encouragement “After discussing the study with my husband; he was very enthusiastic about the study”
4. After reading study information “After reading the study information, I directly emailed and signed up”
5. No specific moment “There was no specific moment. I first had to let the information sink in, because at first I was afraid that it would cost too much time”
11
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3051  | https://doi.org/10.1038/s41598-021-81204-9
www.nature.com/scientificreports/
Discussion
The PIP pilot trial was generally feasible and acceptable. Women were positive about future participation in a 
similar trial, dropout rate was minimal, and compliance to the study protocol high. However, the recruitment 
and acceptability of the trial in practice criteria (i.e., the perceived burden of the study protocol) were not met. 
Secondary data analyses revealed a decrease in pregnancy psychosocial distress, but there was no significant 
difference between the probiotic and placebo groups for these outcomes. Similarly, there were no significant 
differences between the probiotic and placebo groups for the long-term outcomes.
While retention was very high with minimal dropout, recruitment was problematic in this study. Of the 1573 
women screened, 3% were randomized. This randomization rate is similar to the Milgrom et al. (2011) study 
on the effectiveness of a behavioral intervention for reducing depressive symptoms among pregnant  women49. 
However, the participation rate of this study (30%) was lower than the Milgrom et al. (2011) study participa-
tion rate (56%). While women in the Milgrom et al. (2011) study were screened and offered participation at 
clinical centers by midwives, recruitment in the current study was conducted through telephone invitation by a 
researcher, possibly explaining the difference in participation rates between the studies. Clinical staff are indeed 
known good partners to facilitate recruitment by identifying and speaking directly to eligible pregnant women 
about study  protocols50. In light of our results, these approaches might be even more essential for pregnant 
women with psychosocial distress. Future studies investigating food supplements in this population may hence 
Table 5.  Description of reasons for participation in the pilot trial.
Reason Specific elements Representative comments from participants
1. Potential benefits
Personal yield “In my situation it is appealing to me to receive something that might help me, even if it is a placebo effect”
Potential benefit for other people “I’m joining the study because it eventually might help other people to reduce or prevent symptoms”
Potential benefit for healthcare “I had depressive symptoms after my first pregnancy. It would be nice if there was an alternative to medication to reduce depressive symptoms”
Potential benefit for science “I believe it is important to help scientific research, and with that the health of mothers and babies”
Cost/benefit analysis
“I like to contribute to studies which pose no burden on my child and 
which contribute to something I find useful. Given that your study 
included both, I directly signed up to join. To me, research is useful 
when it is more focused on healthy life style and eating patterns than on 
medication”
2. Study topic
Personal interest in (gut) microbiota, mind–body interaction, diet, mood “I choose to join because the research topic appeals to me: the link between the brain/mood/mental wellbeing, the gut and diet”
Prenatal anxiety and depression being a taboo subject “Prenatal anxiety and depression are important themes, but they’re a taboo”
Recognizing oneself in the study population “I am familiar with having depressive symptoms during pregnancy”
Through friends/family being familiar with food supplements, or anxiety 
and depression
“I have a brother who mentally felt much better after taking vitamin D (..) 
and a sister-in-law who was suicidal during her pregnancy”
3. Familiarity with research Probiotic productPrevious participation in research
“I’m joining because this study includes a safe and natural product (I 
would not have participated if a medication would have been tested)”
“In the past, I joined a scientific research study on gut microbiota”
4. Moral obligation Important to participate in scientific research to generate more knowledge “I see it as a moral obligation to join: this research is important and there-fore important to contribute to it”
Figure 2.  Reasons for declining study participation as a percentage of the total number of women who were 
invited to join the pilot trial and provided reasons for declining participation (N = 60).
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consider having midwives or mental healthcare professionals personally introduce the trial to pregnant women. 
In addition, to ensure constant and effective recruitment, a future full trial should invest in strong collaboration 
between researchers, midwives, and mental healthcare  professionals51. Additionally, the results of our qualitative 
analyses showed that the main reason of women to decline study participation was the burden of the study. One 
method to reduce the burden of the study and improve recruitment rates would be meeting with women after 
regular pregnancy care visits and guiding and supporting them through the study’s various steps. Another would 
be to shorten the duration of the study by limiting it to pregnancy (i.e. leaving out child outcome measures). 
Finally, for a larger trial focused on clinical outcomes, the collection of biological samples could be left out. 
Alternatively, recruitment staff should invest more time in better explaining the value of collecting biological 
samples to potential participants.
Although measured in a small population, this study found no effect of probiotics on psychosocial distress 
after 8 weeks of probiotic intake. Note that in our study we investigated group effects of probiotics, while it is 
known that effects can vary from one individual to another. Factors that can influence probiotic effects are host 
 diet52, genetics, age, medication  use53, severity of symptoms (e.g. mild, moderate, severe depression)9, and gut 
microbiota  composition54. In future studies, these factors could be included to assess whether they would predict 
who would benefit from probiotic supplementation. For instance, baseline gut bacterial samples can be collected 
and bacterial profiles used as predictors of probiotic  response55.
The lack of effect of 8 weeks of probiotic intake on psychosocial distress is in contrast with the Slykerman et al. 
(2017) study, which reported a significant positive effect of perinatal maternal probiotic intake on postpartum 
depressive and anxiety  symptoms10. The difference in outcomes may be explained by methodological differences 
between the studies. The Slykerman et al. (2017) study included a substantially larger sample than the current 
study (n = 423) and used Lactobacillus rhamnosus HN001, whereas our sample size was relatively small (n = 40) 
and participants received a probiotic mixture without this strain. A recent meta-analysis indicated that probiotic 
effects are strain and species-specific56. Furthermore, differences in the timing and length of probiotic intake 
may, in part, explain the differences in  outcomes57.
The general reduction of psychosocial distress after 8 weeks of probiotic intake may indicate a natural 
decrease of symptoms. Studies report that anxiety (i.e., state and trait) naturally decreases over  gestation58–60 
and spontaneous improvement of symptoms often occurs in RCTs that include participants with high depres-
sion symptom  scores61. However, it is possible that two other factors played a role in reduction of symptoms: 
participants’ expectancy to respond to the intervention  product62–64 and strong engagement between research 
staff and  participants65,66. In support of the former, the qualitative results of this study showed that most women 
indicated that their main reason for participation was the potential benefit it might bring them. Regarding 
Figure 3.  Depressive symptom scores of women in the probiotic (N = 20) and placebo groups (N = 20) 
measured at baseline (t0), 8 weeks after probiotic/placebo intake (t1) and 4 weeks postpartum (t2). *p < 0.05.
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research staff and participant engagement, a recent RCT investigating the same probiotic product also reported 
a reduction in depressive symptoms after 8 weeks of probiotic and placebo intake, but no significant difference 
between the probiotic and placebo groups. Similar to the current study, research staff was in close contact with 
participants throughout the  study65. Thus, at this point, it is unclear whether the decrease in symptoms after 
8 weeks of product intake was a natural phenomenon that resulted from participants’ expectancy to respond 
to the intervention product, was due to strong engagement between with the research staff, or a combination 
of all factors. Future RCTs with blinded assessment should account for the possible effects of these factors on 
psychosocial distress by including a third control arm receiving no intervention.
The strength of this pilot study is the mixed methods approach of combining both qualitative and quantitative 
measures. This method provided an in depth portrayal of reasons for joining and declining study participation 
in women with psychosocial distress. Other strengths of the study are the inclusion of confounders and the high 
compliance rate of probiotic/placebo intake and mood questionnaires, which provided a realistic and unbiased 
preliminary result of the probiotic/placebo intervention for the secondary outcomes.
Several limitations should be mentioned regarding the study results. First, the study included a relatively small 
sample size to explore potential efficacy of a probiotic product, and therefore these secondary outcomes should 
be interpreted with caution. Second, given that this study did not include a third control arm, the possibility of 
a natural decrease of symptoms should be acknowledged. Third, the study population included a relatively large 
number of women of higher socio-economic status, which hampers the generalizability of the study results. 
Finally, the study included a relatively large number of women with subclinical depressive and anxiety symptoms 
(i.e. without a diagnosis of depression or anxiety disorder). Previous systematic reviews and meta-analyses have 
shown that lower depressive symptom severity is positively associated with a higher placebo response, and thus 
it is possible that the placebo response was relatively high in the current pilot  trial67–69.
The PIP pilot trial was generally feasible and acceptable, but suffered from low recruitment rates. Alterna-
tive methods of recruitment, including active recruitment by healthcare professionals, might be considered in a 
future definitive trial. Although evaluated in a relatively small population, analyses of secondary endpoints did 
not reveal differences between probiotic and placebo groups. In light of the increased risk of adverse maternal 
and infant outcomes for women suffering from prenatal depression and anxiety, future studies should explore the 
potential efficacy of other study designs or other (non) pharmacological treatments. Possibilities are, for example, 
to reduce the number of study measures and to use the same probiotic supplement starting in the first trimester 
Figure 4.  Anxiety symptom scores of women in the probiotic (N = 20) and placebo groups (N = 20) measured at 
baseline (t0), 8 weeks after probiotic/placebo intake (t1) and 4 weeks postpartum (t2).
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of pregnancy, when natural pregnancy changes to the maternal gut microbiota have not yet taken  place70 and the 
probiotic may have a larger effect. Alternatively, the use of other probiotics or combinations of probiotics and 
dietary fibers that promote the activity of the probiotic bacteria should be  explored71,72.
Data availability
The datasets generated during and analyzed during the current study are available from the corresponding author 
on reasonable request.
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